Understanding how metabolism affects healthy and cancerous blood cells
Metabolic control of normal and malignant hematopoiesis
['FUNDING_R37'] · SLOAN-KETTERING INST CAN RESEARCH · NIH-10977722
This research explores how changes in cell metabolism, particularly a molecule called L-2HG, contribute to acute myeloid leukemia (AML) in patients without specific genetic mutations.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SLOAN-KETTERING INST CAN RESEARCH (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10977722 on ClinicalTrials.gov |
What this research studies
We know that certain genetic changes in AML lead to a molecule called D-2HG, which stops cancer cells from maturing. While new medicines target this D-2HG, they only help a specific group of patients. Our work looks at whether a similar molecule, L-2HG, might also play a role in AML for patients who don't have those genetic changes. We found that low oxygen levels can cause both healthy and cancerous cells to make L-2HG, which then helps cancer cells grow and prevents them from developing normally. This suggests that targeting L-2HG could be a new way to help more patients with AML.
Who could benefit from this research
Good fit: This research is relevant for patients diagnosed with acute myeloid leukemia, particularly those whose disease is not driven by IDH mutations.
Not a fit: Patients with other types of cancer or those whose AML is already effectively managed by existing IDH-targeted therapies may not directly benefit from this specific line of inquiry.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies for acute myeloid leukemia, especially for patients whose cancer does not have common genetic mutations.
How similar studies have performed: While IDH inhibitors targeting D-2HG have shown success in specific AML patient subsets, the role of L-2HG in IDH-wildtype AML is a novel area of investigation.
Where this research is happening
NEW YORK, UNITED STATES
- SLOAN-KETTERING INST CAN RESEARCH — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: INTLEKOFER, ANDREW MICHAEL — SLOAN-KETTERING INST CAN RESEARCH
- Study coordinator: INTLEKOFER, ANDREW MICHAEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.